| 1 |
35572726 | SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer. | 2022 |
2 |
| 2 |
32924987 | Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma. | 2021 |
1 |
| 3 |
33169187 | Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed. | 2021 Mar |
2 |
| 4 |
34026617 | Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. | 2021 |
1 |
| 5 |
34140769 | Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity. | 2021 |
1 |
| 6 |
34292495 | Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. | 2021 Dec |
3 |
| 7 |
34445110 | Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer. | 2021 Aug 5 |
3 |
| 8 |
34527325 | The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. | 2021 Aug |
2 |
| 9 |
34795944 | Correlation of EGFR G873R mutation with prognosis of docetaxel in non-small cell lung cancer. | 2021 Oct |
8 |
| 10 |
34976813 | Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1). | 2021 |
1 |
| 11 |
30760168 | Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation. | 2020 Jan |
1 |
| 12 |
32271354 | Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. | 2020 Jun 1 |
1 |
| 13 |
32464632 | The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. | 2020 |
1 |
| 14 |
32574928 | EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells. | 2020 Oct |
3 |
| 15 |
32642151 | Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. | 2020 May |
2 |
| 16 |
30368503 | Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program. | 2019 |
3 |
| 17 |
30719215 | Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. | 2019 Jan 4 |
1 |
| 18 |
31285646 | Structure-based virtual screening and molecular docking for the identification of potential novel EGFRkinase inhibitors against ovarian cancer. | 2019 |
3 |
| 19 |
31388299 | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]. | 2019 |
1 |
| 20 |
31553438 | Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. | 2019 Dec 1 |
1 |
| 21 |
29115057 | Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis. | 2018 May |
1 |
| 22 |
29290252 | Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. | 2018 Jan |
1 |
| 23 |
29542378 | Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. | 2018 Mar |
1 |
| 24 |
29599351 | Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer. | 2018 Apr |
2 |
| 25 |
29615076 | Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. | 2018 Apr 3 |
1 |
| 26 |
29843041 | Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles. | 2018 Sep |
1 |
| 27 |
30066906 | Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. | 2018 Oct |
4 |
| 28 |
30226780 | Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy. | 2018 Nov 5 |
1 |
| 29 |
28017787 | Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. | 2017 Apr |
1 |
| 30 |
28122302 | Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer. | 2017 Apr |
3 |
| 31 |
28337370 | Role of epidermal growth factor receptor in lung cancer and targeted therapies. | 2017 |
1 |
| 32 |
28959367 | Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. | 2017 Oct |
1 |
| 33 |
29033568 | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts. | 2017 |
4 |
| 34 |
29082855 | Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. | 2017 Oct 30 |
2 |
| 35 |
26781399 | Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR. | 2016 |
1 |
| 36 |
27045718 | [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients]. | 2016 Mar 29 |
3 |
| 37 |
27221512 | MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor. | 2016 Jul |
1 |
| 38 |
27274999 | Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. | 2016 |
1 |
| 39 |
27916908 | Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy. | 2016 Nov 30 |
1 |
| 40 |
24888374 | EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). | 2015 Apr |
12 |
| 41 |
25576381 | C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study. | 2015 Mar 1 |
1 |
| 42 |
25854383 | Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment. | 2015 |
1 |
| 43 |
26018524 | Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. | 2015 |
1 |
| 44 |
26081868 | In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer. | 2015 Sep |
2 |
| 45 |
26089726 | An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre. | 2015 Jun |
1 |
| 46 |
26141215 | Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. | 2015 Sep |
3 |
| 47 |
26209642 | Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. | 2015 Oct |
1 |
| 48 |
26259641 | Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents. | 2015 Oct |
4 |
| 49 |
24682085 | Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells. | 2014 Jun |
9 |
| 50 |
24841974 | Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). | 2014 Jun 20 |
1 |